How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,102 results for

Anaphylaxis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8161. Tecemotide (L-BLP25) in Prostate Cancer

, allergic reaction or anaphylaxis (in subjects who have known contrast allergies) are allowed Eastern Co-operative Oncology Group (ECOG) performance status of 0-1 Human leukocyte antigen (HLA)-A2 or A3 positive for immunologic monitoring Hematological and biochemical eligibility parameters as defined in the protocol No other active malignancies within the past 3 years (with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder) Willing to travel to the study center(s) for follow

2011 Clinical Trials

8162. Study of Chlorhexidine Gluconate as a Preoperative Antisepsis

with Drug Side effect. [ Time Frame: Within 1 month ] We check the side effect of our drugs including chlorhexidine and povidione iodine. For example, itching sense, pruritis, ulticaria, redness, anaphylaxis Number of patients with the postoperative sepsis induced by wound infection [ Time Frame: within 1 month ] Definition of Sepsis Proven infection (by culture, stain) or a clinical syndrome pathognomonic for infection (WBC, imaging finding or petechiae, purpura, or purpura fulminans) Body temperature

2011 Clinical Trials

8163. Clinical Study of rhBMP-2/BCP With the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease

( anaphylaxis). Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta). Contacts and Locations Go to No Contacts or Locations Provided More Information Go to Layout table for additonal information Responsible Party: Medtronic Spinal and Biologics ClinicalTrials.gov Identifier: Other Study ID Numbers: C-9807 First Posted: December 19, 2011 Last Update Posted: August 2, 2013 Last Verified

2011 Clinical Trials

8164. Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants

adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain Known or suspected impairment/alteration of immune function, for example receiving immunosuppressive therapy or receiving blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids Bleeding

2011 Clinical Trials

8165. Drug Interaction Study of Isavuconazole and Cyclosporine

The subject has a known or suspected allergy to any of the components of the trial products or the azole class of compounds or a history of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reactions The subject is a smoker (any use of tobacco or nicotine containing products) in the last 6 months The subject has had treatment with prescription drugs or complementary and alternative medicines within 14 days prior to study drug administration, or over-the-counter

2011 Clinical Trials

8166. Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

antibodies or gamma globulins) or collagen. Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation. Has received any previous exposure to any/all BMP's of either human or animal extraction. Has a history of allergy to bovine products or a history of anaphylaxis. Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal

2011 Clinical Trials

8167. A Pilot Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease

therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/ACS implantation. Patient has received any previous exposure to BMP. Patient has a history of severe allergy, an allergy to bovine products, or a history of anaphylaxis. Patient has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers-Danlos syndrome, or osteogenesis imperfecta). Contacts and Locations Go

2011 Clinical Trials

8168. Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease

or Dermatomyositis). Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins). Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation. Has received any previous exposure to any/all BMPs of either human or animal extraction. Has a history of severe allergy (anaphylaxis). Has history of endocrine or metabolic disorder known to affect

2011 Clinical Trials

8169. Usefulness of Lidocaine as Topical Pharyngeal Anaesthesia in Esophagogastroduodenoscopy Under Sedation With Propofol

: Percentage of Participants With Adverse Events in Both Groups [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 2 hours postprocedure ] Hypoxemia (SatO2<90% or >4% if the baseline was under 93%), bradycardia (<60 bpm or >10% from baseline), hypotension (systolic blood pressure under 90 mmHg and/or diastolic 60 mmHg), anaphylactic reaction, aspiration o methaemoglobinemia. Likert Four Elements Scale to Evaluate the Satisfaction of Endoscopist [ Time

2011 Clinical Trials

8170. Egg Oral Immunotherapy

of eosinophilic esophagitis, where egg has been identified as a causative food. A history of anaphylaxis requiring overnight hospitalization. A history of intubation related to asthma and/or a history of an intensive care unit admission for asthma management. A current diagnosis of severe persistent asthma [FEV1 (forced expiratory volume in 1 second) < 60% of predicted, as defined by NHLBI (National Heart, Lung, and Blood Institute) guidelines, despite current therapy]. A current diagnosis of severe atopic

2011 Clinical Trials

8171. Dose Range Finding Study With rBet v1-FV

by allergens activates an immunological cascade leading to the symptoms of Type I allergy including rhinitis, conjunctivitis, asthma, and anaphylactic shock. Allergic Rhinitis is the most common chronic atopic disease and is associated with considerable cost and co-morbidity. Seasonal allergic rhinitis (SAR), triggered by pollen from trees, grasses and weeds, is characterized by sneezing, nasal congestion, nasal itching, rhinorrhea, and pruritic, watery, red eyes. Recombinant preparations offer various

2011 Clinical Trials

8172. BAX 326 Pediatric Study

to Factor IX (FIX) [ Time Frame: Throughout study period (approximately 17 months) ] If more than 2-dilution increase as compared to pre-study level at screening and titers verified for specificity in the confirmatory assay. AB=antibodies in category for outcome measure data. Safety: Number of Participants With Severe Allergic Reactions, e.g. Anaphylaxis [ Time Frame: Throughout study period (approximately 17 months) ] Safety: Number of Participants With Thrombotic Events [ Time Frame: Throughout study (...) . anaphylaxis, following exposure to FIX concentrate(s) Participant has evidence of an ongoing or recent thrombotic disease Participant has an inherited or acquired hemostatic defect other than hemophilia B Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number

2011 Clinical Trials

8173. Single Center Food Allergy Oral Immunotherapy Study

and/or milk and/or tree nut and/or seed allergic subjects between the ages of 4 to 55 years old. Sensitivity to food allergen will be documented by a positive skin prick test result (see Appendix for details) or allergen specific ImmunoCAP IgE level with 7 kU/L as a lower limit of eligibility. Exclusion Criteria: No absolute contraindications are known. However, the risk of serious systemic anaphylactic reactions to food allergens suggests a number of preexisting conditions that should be considered (...) relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers). Subjects having a history of severe anaphylaxis to food allergens that will be desensitized in this study requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma. Contacts and Locations Go to Information from the National

2011 Clinical Trials

8174. Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense

. Patients with a previous history of anaphylaxis Patients with unstable angina Patients with uncontrolled hypertension Patients with clinically significant arrythmias Patients with neoplasia Patients with clinically relevant malformations of the upper respiratory tract. Other chronic or immunological disease that could interfere with the assessment of the investigation product or that could generate any additional risk for the patient Patients who have participated in another clinical trial within 3

2011 Clinical Trials

8175. Subcutaneous Immunotherapy in Patients Sensitized to Dermatophagoides Pteronyssinus (DPT)

, renal or hepatic illnesses or any other medical condition that the investigator deems relevant so as to interfere with the study. Patients with a previous history of anaphylaxis Patients with chronic urticaria Patients with unstable angina Patients with uncontrolled hypertension Patients with clinically significant arrythmias Patients with neoplasia Patients with clinically relevant malformations of the upper respiratory tract. Other chronic or immunological disease that could interfere

2011 Clinical Trials

8176. Tolerance Study of the Silicone Bands on Medical Compression Stockings

of anaphylactic shock. Ongoing antihistamine treatment or having taken during the week before inclusion. Patient on ongoing systemic corticosteroids or having taken corticosteroids in the month before inclusion. Patient having used a topical corticosteroid in the area where the patch tests or prick tests will be performed during the week before inclusion. Phototherapy or sun exposure in the 30 days preceding the skin tests (on the back). Patient having concomitantly used compression stockings and a topical

2011 Clinical Trials

8177. Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

losing enteropathy, nephrotic syndrome). Subject has anemia that would preclude phlebotomy for laboratory studies, according to standard practice at the site. Subject has an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin, SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions. Subject has immunoglobulin A (IgA) deficiency (IgA less than 0.07g/L) and known anti IgA antibodies

2011 Clinical Trials

8178. An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A

of an Investigational Medicinal Product within 30 days prior to the first rVIII-SingleChain administration. Administration of any cryoprecipitate, whole blood or plasma within 30 days prior to administration of rVIII-SingleChain or reference product. Known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein. Any known congenital or acquired coagulation disorder other than congenital FVIII deficiency. Platelet count < 100,000/µL at screening. Human immunodeficiency virus (HIV

2011 Clinical Trials

8179. Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment

, 2015 Sponsor: Meir Medical Center Information provided by (Responsible Party): Arnon Goldberg, Meir Medical Center Study Details Study Description Go to Brief Summary: Beta-lactam allergy is the most prevalent drug allergy. Drug eruption is the most common symptom whereas life-threatening anaphylaxis is rather rare. A recently published study (Journal of Allergy and Clinical Immunology, January 2011, Vol. 127, p. 218-222) described the safety of a 2-day oral beta-lactam challenge in penicillin (...) antibiotic Patients with a diagnosis of penicillin allergy who have no data on the nature of the symptoms that have eventually resulted in establishing this diagnosis Exclusion Criteria: Patients in whom the rash appeared within 1 hour after the last dose of the drug Patients who also developed other anaphylactic symptoms Patients who had a life-threatening rash such as Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis or DRESS. Pregnancy Contacts and Locations Go to Information from the National

2011 Clinical Trials

8180. A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Subjects

anaphylactic reaction to any vaccine or vaccine-related component. Contraindication to vaccination with pneumococcal vaccine. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01531322 Locations Layout table for location information China, Jiangsu Pfizer

2011 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>